| Literature DB >> 25187078 |
Abstract
Mass spectrometry (MS)-based proteomics assays provide unprecedented opportunities for determination of protein expression in tissues for clinical applications. Within the last few years a number of clinical assays have been established. These include multiplexed selected reaction monitoring based approaches to quantify protein targets of therapeutic agents in cancer tissues and bottom-up shotgun MS-based proteomics approaches to diagnose and classify protein deposition disorders such as amyloidosis. These examples highlight the vast potential of MS-based proteomics as analytical and descriptive tools for clinical diagnosis of human disease. However, a number of major challenges remain for broader application and acceptance of such technologies in routine clinical care.Entities:
Keywords: amyloidosis; cancer; immunoglobulin; mass spectrometry; proteomics; transthyretin
Mesh:
Substances:
Year: 2014 PMID: 25187078 DOI: 10.1586/14789450.2014.953062
Source DB: PubMed Journal: Expert Rev Proteomics ISSN: 1478-9450 Impact factor: 3.940